查詢結果分析
來源資料
相關文獻
- A Prospective, Randomized, Controlled Trial to Evaluate the Effect of Prophylactic Sandostatin on Ercp-induced Hyperamylasemia & Pancreatitis
- Serum Level of Amylase and Lipase in Various Stages of Chronic Renal Insufficiency
- Biliary Ascariasis Induced Acute Pancreatitis: A Case Report
- Pancreatico-Pleural Fistula--An Unusual Complication of Pancreatitis
- Effects of Starch Sources on the Production and Activity of Amylase from Bacillus subtilis
- 細胞激素在急性胰臟炎的病因學上扮演的角色
- 藥物引起的胰臟炎
- 急性胰臟炎
- 胰臟微循環與急性胰臟炎
- 血管滲透性與急性胰臟炎
頁籤選單縮合
題 名 | A Prospective, Randomized, Controlled Trial to Evaluate the Effect of Prophylactic Sandostatin on Ercp-induced Hyperamylasemia & Pancreatitis=預防性Sandostatin對ERCP所引起之胰臟炎的效用:一預期性的抽樣對照試驗 |
---|---|
作 者 | 伍錦榮; 江兆豐; 梁中鼎; 吳江水; 陳學全; 楊家麟; 陳素環; 葉治浩; | 書刊名 | 中華民國消化系醫學雜誌 |
卷 期 | 14:2 1997.06[民86.06] |
頁 次 | 頁8-13 |
分類號 | 415.542 |
關鍵詞 | 胰臟炎; 澱粉酵素; 脂肪酵素; ERCP; Pancreatitis; Amylase; Lipase; |
語 文 | 英文(English) |
中文摘要 | ERCP為診斷及治療膽胰系統病變的可靠工具,但是其所引起的併發症不少,而胰臟炎則為常見者之一。Sandostatin是Somatostatin的長效衍生物,可以抑制胰臟分泌。應可用以預防ERCP檢查後所引起的血中澱粉酵素上升及胰臟炎之發生。90位曾經接受ERCP檢查之病患,被任意分為兩組。59位有胰管顯影,其中 29位曾於ERCP檢查前 3分鐘接受 Sandostatin 之預防注射,而其餘 30 位則否,而被當作對照組。結果一位曾接受 Sandostatin 注射的病患,於 ERCP 檢查後發生胰臟炎。另外,在預防注射組中,檢查後60 分鐘,6小時及24小時有高血清澱粉酵素的人數及發生率分別為18(62.1%),20(68.9%)及17(58.6%),而在對照組則分別為17(56.7%),18(60.0%)及18(60.0%),在統計學上兩者並沒有差異。比較兩組在檢查後60分鐘,6小時及24小時的平均血清澱粉酵素及脂肪酵素也是沒有統計學上的差異,所以預防性的Sandostatin注射並不能減少ERCP檢查後所引發的胰臟炎及高血清澱粉酵素之發生率。 |
英文摘要 | ERCP is a well established and reliable procedure in the diagnosis and treatment of pan-creatobiliary tract disorders. Post-ERCP complications are not rare. Among them, pancreatitis is the most common one. Sandostatin, a long-acting analogue of somatostatin, inhibits pancreatic secretion. It seems rational to use it to prevent the rise of amylase and the subsequent occurrence of pancreatitis following ERCP examination. A total of 90 patients who underwent ERCP were randomly allocated into 2 groups. The pancreatic duct was opacified in 59 cases. Among these, 29 patients had been given sandostatin 30 minutes before ERCP while 30 patients served as control. One patient in the prophylactic group developed pancreatitis following ERCP. The incidence of hyperamylasemia following ERCP was 18 (62.1%), 20 (68.9%), 17 (58.6%) in the prophylactic group and 17 (56.7%), 18 (60.0%), 18 (60.0%) in the control group at 60 minutes, 6 hours and 24 hours respectively after each procedure. There was no significant difference between the two groups. Comparison of median serum amylase and lipase levels at 60 minutes, 6 hours and 24 hours after ERCP showed no statistical significance between the prophylactic and control groups. In conclusion, prophylactic sandostatin does not reduce the incidence of pancreatitis and hyperamylasemia following ERCP. |
本系統中英文摘要資訊取自各篇刊載內容。